Literature DB >> 27486666

Nd:YAG Laser Treatment for Extranasal Telangiectasias: A Retrospective Analysis of 38 Patients with Hereditary Hemorrhagic Telangiectasia and Review of the Literature.

Giorgos Papaspyrou1, Bernhard Schick, Basel Al Kadah.   

Abstract

BACKGROUND/AIMS: Extranasal telangiectasias are common amongst hereditary hemorrhagic telangiectasia (HHT) patients. Telangiectasias can be found at sites like the external nose, lips, oral cavity and fingers. Although not life threatening, they can be annoying for patients and lead to bleeding in some cases, necessitating treatment.
METHODS: The data of 38 HHT patients treated for extranasal telangiectasias during a period of 10 years by means of Nd:YAG laser were retrospectively analyzed.
RESULTS: The telangiectasias treated affected predominantly the tongue, facial skin and lips. During a minimum follow-up of 3 years, only 7 patients required a revision of surgery.
CONCLUSION: This study shows that Nd:YAG laser constitutes a fast, safe and efficient therapeutic modality for the treatment of extranasal telangiectasias.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27486666     DOI: 10.1159/000447949

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  2 in total

1.  Combination of Specific Vascular Lasers and Vascular Intense Pulsed Light Improves Facial Telangiectasias and Redness.

Authors:  Luigi Bennardo; Cataldo Patruno; Elena Zappia; Federica Tamburi; Mario Sannino; Francesca Negosanti; Steven Paul Nisticò; Giovanni Cannarozzo
Journal:  Medicina (Kaunas)       Date:  2022-05-11       Impact factor: 2.948

2.  Endoscopic surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia: our experience.

Authors:  Fabio Pagella; Alessandro Pusateri; Eugenia Maiorano; Giuseppe Spinozzi; Sara Ugolini; Roberta Lizzio; Rosolino Mirabella; Carmine Tinelli; Carla Olivieri; Elina Matti
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-02       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.